Tags : Retevmo

Pharma

Eli Lilly’s Retevmo (selpercatinib) Receives the US FDA’s Approval as

Shots: Approval is based on LIBRETTO-001 P-I/II study, which is assessing Retevmo (selpercatinib, 40 mg & 80 mg capsules) in 702 patients with both treatment-naive and heavily pre-treated solid tumour patients (incl. RET fusion-positive NSCLC, RET-mutant MTC, RET fusion-positive thyroid cancer, and other solid tumors with RET alterations) The P-I/II study results (treatment naïve; treatment […]Read More